NASDAQ:IRON

Disc Medicine Opco (IRON) Stock Forecast, Price & News

$49.00

+0.02 (+0.04%)

(As of 09/21/2023 ET)

Compare

Today's Range: $47.52
▼
$49.50
50-Day Range: $45.00
▼
$55.99
52-Week Range: $11.80
▼
$57.70

Volume: 133,571 shs
Average Volume: 247,010 shs
Market Capitalization: $1.12 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $53.78

Disc Medicine Opco MarketRank™ Forecast

Analyst Rating: Buy
3.10 Rating Score
Upside/Downside: 9.8% Upside
$53.78 Price Target
Short Interest: Healthy
2.19% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.41
Based on 8 Articles This Week
Insider Trading: Selling Shares
$77.79 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($3.47) to ($3.90) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.38 out of 5 stars

Medical Sector

908th out of 966 stocks

Pharmaceutical Preparations Industry

427th out of 451 stocks

1.6

Analyst's Opinion

Consensus Rating
Disc Medicine Opco has received a consensus rating of Buy. The company's average rating score is 3.10, and is based on 9 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $53.78, Disc Medicine Opco has a forecasted upside of 9.8% from its current price of $49.00.
Amount of Analyst Coverage
Disc Medicine Opco has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
2.19% of the outstanding shares of Disc Medicine Opco have been sold short.
Short Interest Ratio / Days to Cover
Disc Medicine Opco has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Disc Medicine Opco has recently decreased by 6.24%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Disc Medicine Opco does not currently pay a dividend.
Dividend Growth
Disc Medicine Opco does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IRON.

1.9

News and Social Media Coverage

News Sentiment
Disc Medicine Opco has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Disc Medicine Opco this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for IRON on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Disc Medicine Opco to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Disc Medicine Opco insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $77,786,351.00 in company stock.
Percentage Held by Insiders
Only 4.71% of the stock of Disc Medicine Opco is held by insiders.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Disc Medicine Opco are expected to decrease in the coming year, from ($3.47) to ($3.90) per share.
Price to Book Value per Share Ratio
Disc Medicine Opco has a P/B Ratio of 4.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Disc Medicine Opco (NASDAQ:IRON) Stock

Disc Medicine Opco Inc, together with its subsidiaries, operates as a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The company builds a portfolio of fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. It also develops bitopertin for the treatment of erythropoietic porphyrias, erythropoietic protoporphyria, and X-linked protoporphyria. In addition, the company develops DISC-0974 for the treatment of chronic kidney disease; MWTX-003 for the treatment of polycythemia vera, and other hematologic disorders; and DISC-0998 for the treatment of anemia associated with inflammatory. The company is based in Watertown, Massachusetts.

IRON Price History

30 days | 90 days | 365 days | Advanced Chart

IRON Stock News Headlines

September 20, 2023 | finance.yahoo.com

Disc Medicine Receives FDA Fast Track Designation for MWTX-003 for the Treatment of Polycythemia Vera

September 20, 2023 | americanbankingnews.com

Disc Medicine Opco Inc (NASDAQ:IRON) Short Interest Down 6.2% in August

September 22, 2023 | Wall Street Fundamentals (Ad)

The "Plug and Play" Model Putting Online Giants to Shame

While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."

September 19, 2023 | americanbankingnews.com

Venture Fund X. L.P. Atlas Sells 94,440 Shares of Disc Medicine Opco Inc (NASDAQ:IRON) Stock

September 17, 2023 | americanbankingnews.com

Disc Medicine Opco Inc (NASDAQ:IRON) Given Consensus Rating of "Buy" by Brokerages

September 6, 2023 | finance.yahoo.com

With 52% ownership, Disc Medicine Opco Inc (NASDAQ:IRON) boasts of strong institutional backing

August 30, 2023 | finance.yahoo.com

Disc Medicine to Participate in Upcoming Investor Conferences

August 22, 2023 | seekingalpha.com

Disc Medicine: Rare Disease Developer Derisking Itself

September 22, 2023 | Wall Street Fundamentals (Ad)

The "Plug and Play" Model Putting Online Giants to Shame

July 27, 2023 | finance.yahoo.com

Disc Medicine Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Bitopertin in Diamond-Blackfan Anemia (DBA)

July 26, 2023 | finance.yahoo.com

Here's Why Disc Medicine, Inc. (IRON) Is a Great 'Buy the Bottom' Stock Now

July 12, 2023 | investing.com

Disc Medicine Inc (IRON)

June 22, 2023 | finance.yahoo.com

Disc Medicine Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

June 13, 2023 | finance.yahoo.com

Disc Medicine Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

June 12, 2023 | finance.yahoo.com

Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

June 9, 2023 | finance.yahoo.com

Why Perfectly Rated Disc Medicine, With A 234% Move This Year, Just Put Up Another Big Gain

June 9, 2023 | seekingalpha.com

Disc Medicine: Soaring On EPP Data Release, Reality May Bite On Limited Market Opportunity

June 9, 2023 | finance.yahoo.com

Disc Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress

June 7, 2023 | fool.com

Disc Medicine Opco (NASDAQ: IRON)

June 1, 2023 | finance.yahoo.com

Why Shares of Disc Medicine Opco Climbed This Week

May 31, 2023 | finance.yahoo.com

Disc Medicine to Participate in the Jefferies Healthcare Conference

May 19, 2023 | msn.com

Raymond James Initiates Coverage of Disc Medicine (IRON) with Outperform Recommendation

May 15, 2023 | finance.yahoo.com

Disc Medicine Reports First Quarter 2023 Financial Results and Provides Business Update

May 11, 2023 | finance.yahoo.com

Disc Medicine Announces Presentation of Initial Data from Phase 2 BEACON Trial in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress

May 10, 2023 | finance.yahoo.com

Is a Surprise Coming for Disc Medicine (IRON) This Earnings Season?

May 5, 2023 | finance.yahoo.com

Disc Medicine, Inc. (IRON) is on the Move, Here's Why the Trend Could be Sustainable

May 4, 2023 | finance.yahoo.com

Disc Medicine, Inc. (IRON) Is Up 4.40% in One Week: What You Should Know

See More Headlines

Receive IRON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Disc Medicine Opco and its competitors with MarketBeat's FREE daily newsletter.

IRON Company Calendar

Last Earnings: 8/11/2023
Today: 9/21/2023
Next Earnings (Estimated): 11/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:IRON
CUSIP: N/A
CIK: 1816736
Web: www.discmedicine.com
Phone: 617-401-4400
Fax: N/A
Employees: 55
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $53.78
High Stock Price Forecast: $75.00
Low Stock Price Forecast: $30.00
Forecasted Upside/Downside: +9.8%
Consensus Rating: Buy
Rating Score (0-4): 3.10
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-46,830,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -29.88%
Return on Assets: -28.31%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 39.42
Quick Ratio: 39.42

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $10.15 per share
Price / Book: 4.83

Miscellaneous

Outstanding Shares: 22,878,000
Free Float: 21,800,000
Market Cap: $1.12 billion
Optionable: Not Optionable
Beta: -0.08

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. John D. Quisel Esq. (Age 52)
J.D., Ph.D., CEO, Pres, Sec. & Director
Comp: $750.12k

Ms. Joanne Bryce CPA (Age 56)
Chief Financial Officer
Comp: $539.32k

Mr. Jonathan Yu (Age 42)
Chief Bus. Officer
Comp: $539.32k

Dr. William Jacob Savage M.D. (Age 48)
Ph.D., Chief Medical Officer
Comp: $571.95k

Dr. Brian MacDonald ChB (Age 63)
MB, Ph.D., Founder & Chief Innovation Officer

Dr. Rahul Khara J.D. (Age 41)
Pharm.D., Gen. Counsel, Compliance Officer & Sec.

Mr. Srikanth Venkatraman Ph.D.
Sr. VP & Head of Chemistry

Ms. Hua Yang Ph.D.
Sr. VP of Nonclinical Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IRON Stock - Frequently Asked Questions

Should I buy or sell Disc Medicine Opco stock right now?: 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Disc Medicine Opco in the last year. There are currently 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IRON shares.
View IRON analyst ratings or view top-rated stocks.
What is Disc Medicine Opco's stock price forecast for 2023?: 10 brokerages have issued 12-month target prices for Disc Medicine Opco's shares. Their IRON share price forecasts range from $30.00 to $75.00. On average, they anticipate the company's stock price to reach $53.78 in the next year. This suggests a possible upside of 9.8% from the stock's current price.
View analysts price targets for IRON or view top-rated stocks among Wall Street analysts.
How have IRON shares performed in 2023?: Disc Medicine Opco's stock was trading at $17.95 on January 1st, 2023. Since then, IRON shares have increased by 173.0% and is now trading at $49.00.
View the best growth stocks for 2023 here.
Are investors shorting Disc Medicine Opco?: Disc Medicine Opco saw a decline in short interest in August. As of August 31st, there was short interest totaling 502,000 shares, a decline of 6.2% from the August 15th total of 535,400 shares. Based on an average daily volume of 234,400 shares, the short-interest ratio is currently 2.1 days.
View Disc Medicine Opco's Short Interest.
When is Disc Medicine Opco's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our IRON earnings forecast.
How were Disc Medicine Opco's earnings last quarter?: Disc Medicine Opco Inc (NASDAQ:IRON) announced its quarterly earnings results on Friday, August, 11th. The company reported ($0.74) earnings per share for the quarter, topping the consensus estimate of ($0.86) by $0.12.

What ETFs hold Disc Medicine Opco's stock?: ETFs with the largest weight of Disc Medicine Opco (NASDAQ:IRON) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH).Virtus LifeSci Biotech Clinical Trials ETF (BBC).
What is Disc Medicine Opco's stock symbol?: Disc Medicine Opco trades on the NASDAQ under the ticker symbol "IRON."
Who are Disc Medicine Opco's major shareholders?: Disc Medicine Opco's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Bain Capital Life Sciences Investors LLC (6.73%), Perceptive Advisors LLC (3.75%), Citadel Advisors LLC (3.29%), BlackRock Inc. (2.54%), Polar Capital Holdings Plc (2.15%) and Rock Springs Capital Management LP (1.84%). Insiders that own company stock include Brian Richard Macdonald, Holdings A/S Novo, Joanne Bryce, Kevin Bitterman, Venture Fund X LP Atlas and William Jacob Savage.
View institutional ownership trends.
How do I buy shares of Disc Medicine Opco?: Shares of IRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Disc Medicine Opco's stock price today?: One share of IRON stock can currently be purchased for approximately $49.00.
How much money does Disc Medicine Opco make?: Disc Medicine Opco (NASDAQ:IRON) has a market capitalization of $1.12 billion.
How can I contact Disc Medicine Opco?: Disc Medicine Opco's mailing address is 297 Boston Post Road #248, Wayland MA, 01778. The official website for the company is www.discmedicine.com. The company can be reached via phone at 617-401-4400 or via email at ir@geminitherapeutics.com.

This page (NASDAQ:IRON) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial